Literature DB >> 12466876

Impact of the first Streptomyces genome sequence on the discovery and production of bioactive substances.

S Donadio1, M Sosio, G Lancini.   

Abstract

An important addition to the field of bacterial genomics is the recent publication of the complete genome sequence of Streptomyces coelicolor. This strain has been for some decades the model organism for streptomycetes and other filamentous actinomycetes, Gram-positive bacteria highly valuable for their ability to produce thousands of bioactive metabolites, many of which have found important applications in medicine and agriculture. We discuss here the impacts that the S. coelicolor genome sequence is likely to have on the production of bioactive metabolites by current industrial strains, on the possible development of future superhost(s) for the production of valuable drugs, and on the search for new bioactive substances from microbial sources.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12466876     DOI: 10.1007/s00253-002-1143-0

Source DB:  PubMed          Journal:  Appl Microbiol Biotechnol        ISSN: 0175-7598            Impact factor:   4.813


  3 in total

1.  Activation of the dormant secondary metabolite production by introducing gentamicin-resistance in a marine-derived Penicillium purpurogenum G59.

Authors:  Yun-Jing Chai; Cheng-Bin Cui; Chang-Wei Li; Chang-Jing Wu; Cong-Kui Tian; Wei Hua
Journal:  Mar Drugs       Date:  2012-03-02       Impact factor: 6.085

2.  A molecular key for building hyphae aggregates: the role of the newly identified Streptomyces protein HyaS.

Authors:  Ilona Koebsch; Jens Overbeck; Sophie Piepmeyer; Holger Meschke; Hildgund Schrempf
Journal:  Microb Biotechnol       Date:  2009-02-23       Impact factor: 5.813

3.  Fecal Microbiota, Fecal Metabolome, and Colorectal Cancer Interrelations.

Authors:  Rashmi Sinha; Jiyoung Ahn; Joshua N Sampson; Jianxin Shi; Guoqin Yu; Xiaoqin Xiong; Richard B Hayes; James J Goedert
Journal:  PLoS One       Date:  2016-03-25       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.